Expression of S100A2 calcium-binding protein predicts response to pancreatectomy for pancreatic cancer.
OBJECTIVE
Current methods of preoperative staging and predicting outcome following pancreatectomy for pancreatic cancer (PC) are inadequate. We evaluated the utility of multiple biomarkers from distinct biologic pathways as potential predictive markers of response to pancreatectomy and patient survival.


METHODS
We assessed the relationship of candidate biomarkers known, or suspected, to be aberrantly expressed in PC, with disease-specific survival and response to therapy in a cohort of 601 patients.


RESULTS
Of the 17 candidate biomarkers examined, only elevated expression of S100A2 was an independent predictor of survival in both the training (n = 162) and validation sets (n = 439; hazard ratio [HR], 2.19; 95% confidence interval [CI]: 1.48-3.25; P < .0001) when assessed in a multivariate model with clinical variables. Patients with high S100A2 expressing tumors had no survival benefit with pancreatectomy compared with those with locally advanced disease, whereas those without high S100A2 expression had a survival advantage of 10.6 months (19.4 vs 8.8 months, respectively) and a HR of 3.23 (95% CI: 2.39-4.33; P < .0001). Of significance, patients with S100A2-negative tumors had a significant survival benefit from pancreatectomy even in the presence of involved surgical margins (median, 15.7 months; P = .0007) or lymph node metastases (median, 17.4 months; P = .0002).


CONCLUSIONS
S100A2 expression is a good predictor of response to pancreatectomy for PC and suggests that high S100A2 expression may be a marker of a metastatic phenotype. Prospective measurement of S100A2 expression in diagnostic biopsy samples has potential clinical utility as a predictive marker of response to pancreatectomy and other therapies that target locoregional disease.
Cancer Research Program, Garvan Institute of Medical Research, Darlinghurst, Sydney, NSW, Australia. a.biankin@garvan.org.au
Andrew V
AV
Biankin
James G
JG
Kench
Emily K
EK
Colvin
Davendra
D
Segara
Christopher J
CJ
Scarlett
Nam Q
NQ
Nguyen
David K
DK
Chang
Adrienne L
AL
Morey
C-Soon
CS
Lee
Mark
M
Pinese
Samuel C L
SC
Kuo
Johana M
JM
Susanto
Peter H
PH
Cosman
Geoffrey J
GJ
Lindeman
Jane E
JE
Visvader
Tuan V
TV
Nguyen
Neil D
ND
Merrett
Janindra
J
Warusavitarne
Elizabeth A
EA
Musgrove
Susan M
SM
Henshall
Robert L
RL
Sutherland
D000230:Adenocarcinoma / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000032:analysis / Q000378:metabolism*; D015331:Cohort Studies; D016001:Confidence Intervals; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D010180:Pancreatectomy / Q000379:methods / Q000401:mortality*; D010190:Pancreatic Neoplasms / Q000235:genetics / Q000401:mortality / Q000601:surgery*; D011183:Postoperative Complications / Q000401:mortality; D011237:Predictive Value of Tests; D011336:Probability; D016016:Proportional Hazards Models; D018570:Risk Assessment; D009418:S100 Proteins / Q000235:genetics / Q000378:metabolism*; D012680:Sensitivity and Specificity; D015996:Survival Rate; D013997:Time Factors; D016896:Treatment Outcome
D014408:Biomarkers, Tumor; D009418:S100 Proteins